New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs Livagen

PT-141 (Bremelanotide) vs Livagen

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Anti-Aging & Longevity
Livagen
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
2–3 hours
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.5–1.75 mg
10 mg per day
Frequency
As needed (not daily)
Daily for 10–30 days
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With